Acute kidney injury-focused AM-Pharma raises €29.2 million in series D round
This article was originally published in Scrip
Executive Summary
AM-Pharma, a Dutch biotech company developing an alkaline phosphatase treatment for severe inflammatory disease, has raised €29.2 million in series D financing.